| abstract |
The present disclosure provides a method of treating a disease in a mammal selected from the group consisting of membranous nephropathy (MN), IgG4-related disease, and antiphospholipid syndrome (APS), using, for example, a therapeutically effective amount of a BTK inhibitor 2-[( 3R)‑3‑[4‑amino‑3‑(2‑fluoro‑4‑phenoxy‑phenyl)pyrazolo[3,4‑d]pyrimidin‑1‑yl]piperidine‑1‑carbonyl]‑ 4-methyl-4-[4-(oxetane-3-yl)piperazin-1-yl]pent-2-enenitrile or a pharmaceutically acceptable salt thereof. |